SLC30A8

SLC30A8
Identifiers
Aliases SLC30A8, ZNT8, ZnT-8, solute carrier family 30 member 8
External IDs OMIM: 611145 MGI: 2442682 HomoloGene: 13795 GeneCards: SLC30A8
Genetically Related Diseases
type 2 diabetes mellitus, obesity, asthma[1]
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez

169026

239436

Ensembl

ENSG00000164756

ENSMUSG00000022315

UniProt

Q8IWU4

Q8BGG0

RefSeq (mRNA)

NM_001172811
NM_001172813
NM_001172814
NM_001172815
NM_173851

NM_172816

RefSeq (protein)

NP_001166282.1
NP_001166284.1
NP_001166285.1
NP_001166286.1
NP_776250.2

NP_766404.1

Location (UCSC) Chr 8: 116.95 – 117.18 Mb Chr 15: 52.3 – 52.34 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

Solute carrier family 30 (zinc transporter), member 8, also known as SLC30A8, is a human gene[4] that codes for a zinc transporter related to insulin secretion in humans. Certain alleles of this gene may increase the risk for developing type 2 diabetes, but a loss-of-function mutation appears to greatly reduce the risk of diabetes.[5]

Clinical significance

Association with type 2 diabetes (T2D)

12 rare variants in SLC30A8 have been identified through the sequencing or genotyping of approximately 150,000 individuals from 5 different ancestry groups. SLC30A8 contains a common variant (p.Trp325Arg), which is associated with T2D risk and levels of glucose and proinsulin.[6][7][8] Individuals carrying protein-truncating variants collectively had 65% reduced risk of T2D. Additionally, non-diabetic individuals from Iceland harboring a frameshift variant p. Lys34Serfs*50 demonstrated reduced glucose levels.[5] Earlier functional studies of SLC30A8 suggested that reduced zinc transport increased T2D risk.[9][10] Conversely, loss-of-function mutations in humans indicate that SLC30A8 haploinsufficiency protects against T2D. Therefore, ZnT8 inhibition can serve as a therapeutic strategy in preventing T2D.[5]

See also

References

  1. ↑ "Diseases that are genetically associated with SLC30A8 view/edit references on wikidata".
  2. ↑ "Human PubMed Reference:".
  3. ↑ "Mouse PubMed Reference:".
  4. ↑ "Entrez Gene: SLC30A8 solute carrier family 30 (zinc transporter), member 8".
  5. 1 2 3 Flannick, Jason; et al. (2014). "Loss-of-function mutations in SLC30A8 protect against type 2 diabetes". Nature Genetics. 46: 357–363. doi:10.1038/ng.2915.
  6. ↑ Dupis, J.; et al. (Feb 2010). "New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk.". Nature Genetics. 42 (2): 105–16. doi:10.1038/ng.520. PMID 20081858.
  7. ↑ Strawbridge, R.J.; et al. (October 2011). "Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes.". Diabetes. 60 (10): 2624–34. doi:10.2337/db11-0415. PMC 3178302Freely accessible. PMID 21873549.
  8. ↑ Morris, A.P.; et al. (Sep 2012). "Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes.". Nature Genetics. 44 (9): 981–90. doi:10.1038/ng.2383. PMC 3442244Freely accessible. PMID 22885922.
  9. ↑ Nicolson, T.J.; et al. (Sep 2009). "Insulin storage and glucose homeostasis in mice null for the granule zinc transporter ZnT8 and studies of the type 2 diabetes–associated variants.". Diabetes. 58 (9): 2070–83. doi:10.2337/db09-0551. PMID 19542200.
  10. ↑ Rutter, G.A.; et al. "Think zinc: new roles for zinc in the control of insulin secretion.". Islets. 2 (1): 49–50. doi:10.4161/isl.2.1.10259. PMID 21099294.

Further reading


This article is issued from Wikipedia - version of the 8/13/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.